Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies
Portfolio Pulse from
Cognition Therapeutics has completed the final patient visits for its Phase 2 SHIMMER study of CT1812, targeting dementia with Lewy bodies. Topline results are expected in December 2024.
November 26, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cognition Therapeutics has completed the final patient visits for its Phase 2 SHIMMER study of CT1812, targeting dementia with Lewy bodies. Topline results are expected in December 2024.
The completion of patient visits in a clinical trial is a significant milestone, but the impact on the stock price is neutral in the short term as the results are not expected until December 2024. Investors may view this as a positive step in the drug development process, but without immediate results, the stock price is unlikely to be significantly affected.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100